Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

被引：0
|
作者：
Song Mu
Zhiyu Tang
William Novotny
Manal Tawashi
Ta-Kai Li
Ying Ou
Srikumar Sahasranaman
机构：
[1] BeiGene USA,Clinical Pharmacology
[2] BeiGene USA,Clinical Development
[3] BeiGene USA,Clinical Operations
[4] BeiGene USA,Drug Safety and Pharmacovigilance
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Clinical pharmacology; Clinical trials; Drug–drug interactions; Oncology; Pharmacokinetics and drug metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：391 / 399
页数：8
相关论文
共 50 条
  • [41] Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
    Rhodes, Joanna M.
    Mato, Anthony R.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 919 - 926
  • [42] Pharmacokinetics (PK) and pharmacogenetics (PG) of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
    Dymond, A.
    Elks, C.
    Martin, P.
    Carlile, D.
    Mariani, G.
    Lovick, S.
    Huang, Y.
    Lorch, U.
    Brown, H.
    So, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Evaluating the effect of a Bruton's tyrosine kinase inhibitor in a murine experimental autoimmune encephalomyelitis model of multiple sclerosis
    Gruber, R. C.
    Blazier, A. S.
    Lee, L.
    Ryan, S.
    Chong, A.
    Havari, E.
    Turner, T. J.
    Ofengeim, D.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 244 - 245
  • [44] Evaluating the Effect of a Bruton's Tyrosine Kinase Inhibitor in a Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis
    Gruber, Ross
    Blazier, Anna
    Lee, Lan
    Ryan, Sean
    Cheong, Agnes
    Havari, Evis
    Turner, Timothy
    Ofengeim, Dimitry
    NEUROLOGY, 2023, 100 (17)
  • [45] Protective Effect of Bruton Tyrosine Kinase Inhibitor in Theiler's Murine Encephalomyelitis Virus Model of Chronic Demyelination
    Pol, Suyog
    Dhanraj, Ravendra
    Ding, Ying Ying
    Zivadinov, Robert
    NEUROLOGY, 2021, 96 (15)
  • [46] A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
    Smith, Patrick F.
    Krishnarajah, Janakan
    Nunn, Philip A.
    Hill, Ron J.
    Karr, Dane
    Tam, D.
    Masjedizadeh, Mohammad
    Funk, Jens O.
    Gourlay, Steve G.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (11) : 2367 - 2376
  • [47] Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system
    Wang, Yali
    Han, Jiefei
    Yin, Shuo
    Yang, Shoubo
    Kang, Xun
    Zheng, Xiaohong
    Duan, Ling
    Li, Shenglan
    Jiang, Bo
    Li, Wenbin
    Chen, Feng
    LEUKEMIA & LYMPHOMA, 2025,
  • [48] Optimization of formulation and treatment regimen of BIIB091, a non-covalent Bruton's tyrosine kinase inhibitor
    Tsai, Hui-Hsin
    Park, Gab-jin
    Milad, Mark
    Zann, Vanessa
    Evans, Phil
    Lin, Wu
    Chiu, Yi-Da
    Riester, Katherine
    Bame, Eris
    Sweet-Smith, Sue
    Torres, Jorge A.
    Soliman, Michael
    Hanna, Jerome
    Zhu, Bing
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 932 - 932
  • [49] Discovery and Development of Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)
    Crawford J.J.
    Zhang H.
    ACS Symposium Series, 2019, 1332 : 239 - 266
  • [50] Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy
    Park, Hyun Young
    Chae, Min Kyung
    Ko, JaeSang
    Kikkawa, Don O.
    Jang, Sun Young
    Yoon, Jin Sook
    PLOS ONE, 2022, 17 (12):
12345